A best-in-class long-acting amylin analog targeting the $15B metabolic disease market, specifically obesity and type 2 diabetes mellitus (T2DM). This injectable hormone therapy acts as an amylin/calcitonin receptor agonist with weekly dosing convenience.
Transforming cardiovascular and oncology treatment with the first oral small molecule PCSK9 inhibitor, delivering unmatched patient convenience and expanded access to life-saving therapy.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.